SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-21-137021
Filing Date
2021-11-10
Accepted
2021-11-10 16:58:52
Documents
4
Period of Report
2021-12-22

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm2132544d1_pre14a.htm PRE 14A 108927
2 GRAPHIC tm2132544d1_pre14aimg001.jpg GRAPHIC 4172
3 GRAPHIC tm2132544d1_pre14aimg01.jpg GRAPHIC 104007
4 GRAPHIC tm2132544d1_pre14aimg02.jpg GRAPHIC 164428
  Complete submission text file 0001104659-21-137021.txt   486030
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37558 | Film No.: 211397589
SIC: 2834 Pharmaceutical Preparations